Boston Scientific Cash Flow Statement
NYSE: BSXHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Boston Scientific free cash flow
In fiscal 2025, Boston Scientific generated $4.53 billion of operating cash flow and spent $876.0 million on capital expenditures. That left free cash flow of $3.66 billion, a free-cash-flow margin of 18.2% of revenue. Free cash flow was up 38.3% from the prior year's $2.65 billion.
Summary generated from market data by MetaCap's automated system. Methodology
Boston Scientific cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 2.89B | 1.85B | 1.59B | 698.00M | 1.04B | -82.00M | 4.70B | 1.67B | 104.00M | 347.00M |
| Net Income growth (YoY) | +56.66% | +15.95% | +128.08% | -32.95% | — | -101.74% | +181.27% | +1506.73% | -70.03% | — |
| Depreciation & Amortization | 1.37B | 1.27B | 1.20B | 1.14B | 1.09B | 1.12B | 1.01B | 894.00M | 844.00M | 815.00M |
| Stock-Based Compensation | 299.00M | 266.00M | 233.00M | 220.00M | 194.00M | 170.00M | 157.00M | 140.00M | 127.00M | 116.00M |
| Change in Working Capital | -246.00M | -462.00M | -770.00M | -1.00B | -351.00M | -139.00M | -314.00M | -2.17B | 38.00M | 334.00M |
| Operating Cash Flow | 4.53B | 3.44B | 2.50B | 1.53B | 1.87B | 1.51B | 1.84B | 310.00M | 1.43B | 1.18B |
| Capital Expenditures | -876.00M | -790.00M | -711.00M | -588.00M | -554.00M | -376.00M | -461.00M | -316.00M | -319.00M | -376.00M |
| Investing Cash Flow | -2.64B | -5.69B | -2.57B | -2.01B | -1.60B | -411.00M | -5.04B | -1.92B | -1.01B | -887.00M |
| Dividends Paid | — | 0 | -28.00M | -55.00M | -55.00M | -28.00M | 0 | 0 | — | — |
| Share Repurchases | — | — | — | 0 | 0 | -535.00M | 0 | 0 | — | 0 |
| Debt Issued | 1.56B | 2.15B | 0 | 3.27B | 0 | 1.68B | 7.23B | 987.00M | 0 | 0 |
| Debt Repaid | — | 0 | 0 | -3.18B | 0 | -1.26B | -3.56B | -602.00M | -1.00B | -250.00M |
| Financing Cash Flow | -395.00M | 1.81B | 5.00M | -548.00M | -95.00M | 293.00M | 2.97B | 1.43B | 110.00M | -206.00M |
| Net Change in Cash | 1.54B | -450.00M | -70.00M | -1.04B | 173.00M | 1.39B | -222.00M | -188.00M | 530.00M | -123.00M |
| Free Cash Flow | 3.66B | 2.65B | 1.79B | 938.00M | 1.32B | 1.13B | 1.38B | -6.00M | 1.11B | 806.00M |
This table shows 10 annual periods of Boston Scientific's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BSX's reporting calendar. What is a cash flow statement?